Alector's Stock Price Target Drops Amid Clinical Setback, Analysts Reassess Risks and Opportunities

Alector's consensus analyst price target has dropped from $2.20 to $2.05 per share after negative late-stage clinical data. Analysts have reassessed the risks and opportunities for the stock, with some noting the company's other pipeline candidates and cost-cutting measures as potential positives. However, others have downgraded the stock and reduced their price targets, citing high risks in Alzheimer's disease drug development and a lack of near-term catalysts.